Allison DeAngelis and Adam Feuerstein

BioTech

Listen: A new obesity startup, an acquisition gone wrong, & the future of Teladoc

How does a startup compete with the likes of Eli Lilly and Novo Nordisk in the rapidly evolving field of weight loss drugs? And how

Allison DeAngelis and Adam Feuerstein April 18, 2024

BioTech

Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise

Why is it surprising when drug executives stay true to their word? And can neoantigen cancer vaccines work? We cover all that and more this

Allison DeAngelis and Adam Feuerstein April 4, 2024

BioTech

A CRISPR milestone, algorithms amok, & biotech mixology

Who polices algorithms? How would you name the first approved CRISPR medicine? And what pairs well with a biotech downturn? We cover all that and

Allison DeAngelis and Adam Feuerstein November 16, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.

Allison DeAngelis and Adam Feuerstein

Listen: A new obesity startup, an acquisition gone wrong, & the future of Teladoc

Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise

A CRISPR milestone, algorithms amok, & biotech mixology

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

Subscribe